Phase 2 N=50 A Study of AGEN2034 in Advanced Tumors and Cervical Cancer
Advanced Cancer · Cervical Cancer
Primary: Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) for Balstilimab — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=130 Incentives and Glucose Adherence in Diabetes
Diabetes in Pregnancy
Primary: Frequency of Glucose Monitoring — 57.31; 58.48; 69.08 percentage of overall adherence
N/A N=291 Randomized Trial Of Achieving Healthy Lifestyles In Psych Rehabilitation
Overweight and Obesity
Primary: Change in Weight Loss in Kilograms (kg) — -1.8; -0.3; -3.4; -0.2 kg
Phase 3 N=271 Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial
Sickle Cell Disease
Primary: Time-to-crisis Resolution — 81.5; 88.6 hours
N/A N=14 CONFIDENCE-AI Financial Education for Caregivers (CONFIDENCE-AI)
Alzheimer Disease · Dementia · Caregiver Burden
Primary: Financial Strain — -3.4; -4.7 units on a scale
N/A N=800 Validation of Falls Decision Rule to Exclude Intracranial Bleeding in Geriatric Fall Patients
Intracranial Hemorrhages
Primary: Number of Participants With the Clinically Important Intracranial Bleeding — 48; 1 Participants
N/A N=61 Increasing Treatment Efficacy Using SMART Methods for Personalizing Care
Anxiety Disorders · Post Traumatic Stress Disorder · Obsessive-Compulsive Disorder
Primary: Change in Clinical Severity From Baseline to 6 Weeks (Brief Intervention) or 12 Weeks (Full Intervention) — -2.40; -2.86; -2.71; -2.00 score on a scale
Phase 2 N=13 Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
Advanced Pancreatic Carcinoma · Locally Advanced Pancreatic Carcinoma · Metastatic Pancreatic Carcinoma
Primary: Tumor Response — 5; 3 Participants
Phase 1 N=73 First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants
HIV Infections
Primary: Part 1: Number of Participants With Any Adverse Events (AEs) and by Severity — 4; 2; 3; 0 Participants
Phase 3 N=133 Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection
Pancreatic Cancer
Primary: Number of Incidences of Grade 3 or Greater Complications — 0; 0 Number of complications
N/A N=5 Validation of a Knee Brace for Gonarthrosis
Gonarthrosis
Primary: Ease of Use Measurement Scale — 4.05; 3.00; 4.05 score on a scale
Phase 3 N=207 A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
Partial Seizures With or Without Secondary Generalization · Epilepsy
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 88.9; 95.5; 100; 94.1 percentage of participants
N/A N=53 Implementation Strategy Resource Package for Behavioral Classroom Interventions: Pilot Test
Attention Deficit Hyperactivity Disorder Symptoms
Primary: Feasibility of Intervention Measure — 4.52 score on a scale
Phase 3 N=122 Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
Immune Thrombocytopenia
Primary: Proportion of Patients With a Platelet Response — 52; 14 Participants
N/A N=64 Needling Techniques for Knee Osteoarthritis
Knee Osteoarthritis · Kidney Yin Deficiency · Kidney Yang Deficiency
Primary: WOMAC Total in Week 15 — 11.6; 54.4 score on a scale — p=<0.001